JD Health International Inc. JD Health International Inc.

JD Health International Inc.

6618

주식 순위 #1399
JD Health International Inc., functioning as an investment holding entity, runs... JD Health International Inc., functioning as an investment holding entity, runs an expansive digital healthcare platform across the People's Republic of China. The company supplies a diverse range of pharmaceutical and wellness products, such as over-the-counter and prescription medications, medical devices, and health supplements. These goods are distributed through both direct sales and an extensive online retail pharmacy network. Beyond product offerings, its comprehensive service suite includes virtual medical consultations, patient referrals to hospitals and doctors, health screening programs, genetic testing, and beauty care services. Additionally, it develops intelligent healthcare and wellness management solutions, alongside providing technical support and advertising services. The platform also facilitates access to various medical provisions, including general health examinations, cosmetic medical procedures, vaccination bookings, dental treatments, and nucleic acid testing. Incorporated in 2018 and headquartered in Beijing, People's Republic of China, JD Health International Inc. is a subsidiary of JD Jiankang Limited.
주가
$4.98
시가총액
$15.89B
변동 (1일)
-2.21%
변동 (1년)
-39.77%
국가
CN
거래 JD Health International Inc. (6618)

카테고리

Healthcare
JD Health International Inc. (6618)의 발행 주식 수
June 2026 기준 발행 주식 수: 3.18B
JD Health International Inc.의 최신 재무 보고서와 주가에 따르면 현재 발행 주식 수는 3.18B입니다. December 2023 말 기준 회사는 3.15B주를 발행했습니다. 발행 주식 수는 일반적으로 주식 분할이나 자사주 매입에 의해 영향을 받습니다.
JD Health International Inc. (6618)의 발행 주식 수 기록 (2017 ~ 2026)
매년 말 기준 발행 주식 수
연도 발행 주식 수 변화
2026 (TTM) 3.18B 0.78%
2024 3.15B 0.10%
2023 3.15B 1.38%
2022 3.11B 0.39%
2021 3.09B 40.13%
2020 2.21B 2.76%
2019 2.15B -31.27%
2018 3.13B 0.00%
2017 3.13B 0.00%
유사 기업 또는 경쟁사의 발행 주식 수
회사 발행 주식 수 차이 국가
222.83M -92.99%
US
- -
DE
83.52M -97.37%
US
350.00M -88.99%
SA
2.18B -31.39%
BR